10-QPeriod: Q3 FY1996

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 1996

Filed November 13, 1996For Securities:LLY

Summary

Eli Lilly and Company's (LLY) 10-Q filing for the period ending September 29, 1996, indicates a company in a period of reporting without specific financial performance details provided in the filing text. The filing's content is primarily navigational and administrative, directing users to access the full report data within the SEC's EDGAR system. Investors seeking detailed financial health, revenue figures, profitability, or strategic developments would need to access the actual .txt or .html documents from the provided archive path. As this excerpt focuses on the filing's structure and metadata rather than its financial narrative, it's impossible to provide concrete performance insights. However, the fact that the company is filing its quarterly report signifies ongoing operational activity and adherence to regulatory disclosure requirements. Investors should consult the full financial statements within the report for a comprehensive understanding of Lilly's performance during this quarter.

Key Highlights

  • 1The filing is a 10-Q Quarterly Report for Eli Lilly & Co (LLY) for the period ending September 29, 1996.
  • 2The report was filed with the SEC on November 12, 1996.
  • 3The provided content is a directory listing from the SEC's EDGAR archives, not the financial statements themselves.
  • 4Key financial data, operational highlights, and management discussion are not present in this excerpt.
  • 5Investors must access the linked .txt or .html files within the EDGAR system for detailed financial information.
  • 6The filing confirms Lilly's compliance with quarterly reporting obligations.

Frequently Asked Questions

The actual financial results, including revenue, expenses, and profitability, are contained within the full 10-Q report document. You would need to access the .txt or .html files linked within the SEC's EDGAR archive provided in the filing details (e.g., '-96-000007.txt' or '-96-000007-index.html').

No, the excerpt provided is a directory listing and does not contain specific details about Eli Lilly's product pipeline, sales figures, or strategic initiatives. This information would be found in the narrative sections of the full 10-Q report.

A 10-Q filing is a mandatory quarterly report filed by public companies with the U.S. Securities and Exchange Commission (SEC). It provides a comprehensive overview of the company's financial performance and condition during the reported quarter, including unaudited financial statements, management's discussion and analysis, and other relevant disclosures.